Khartis Therapeutics secures $50 million Series B funding from Forge Life Science Partners, Longwood Fund and Lilly Asia Ventures
read at Endpoints ↗DealPositive
San Diego-based Khartis Therapeutics announced a $50 million Series B financing round.
The round was led by Forge Life Science Partners and included participation from Longwood Fund, Lilly Asia Ventures and other investors, adding to the company’s existing capital base.
The new funding will be used to advance development of Khartis’s TED drug program and further expand its pipeline.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Zealand's royalty deal; Khartis raises money for TED drug”
read at Endpoints ↗79 words · retrieved Aug 13
comments(0)
5-min edit window · permanent after that